IWC
NBIX icon

Integrated Wealth Concepts’s Neurocrine Biosciences NBIX Stock Holding History

Integrated Wealth Concepts’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.81M Buy
13,744
+7,085
+106% +$940K 0.01% 796
2025
Q4 		$944K Sell
6,659
-1,490
-18% -$216K 0.01% 796
2025
Q3 		$1.14M Buy
8,149
+3,796
+87% +$514K 0.01% 914
2025
Q2 		$547K Sell
4,353
-2,880
-40% -$330K 0.01% 1221
2025
Q1 		$800K Buy
7,233
+4,526
+167% +$573K 0.01% 923
2024
Q4 		$370K Buy
2,707
+757
+39% +$93.6K ﹤0.01% 1261
2024
Q3 		$225K Sell
1,950
-143
-7% -$19.6K ﹤0.01% 1506
2024
Q2 		$288K Sell
2,093
-1
-0% -$137 ﹤0.01% 1341
2024
Q1 		$289K Buy
2,094
+34
+2% +$4.64K ﹤0.01% 1340
2023
Q4 		$271K Buy
2,060
+10
+0.5% +$1.15K ﹤0.01% 1315
2023
Q3 		$231K Buy
+2,050
New +$216K ﹤0.01% 1347

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Integrated Wealth Concepts's NBIX Position: Q1 2026 in Review

Integrated Wealth Concepts increased its Neurocrine Biosciences (NBIX) stake by 106% in Q1 2026, buying an estimated $940K and bringing the position to 13,744 shares worth $1.81M. The position accounts for 0.01% of the portfolio, ranked #796.

Integrated Wealth Concepts first reported a position in NBIX in Q3 2023 and has held it in 11 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Integrated Wealth Concepts held 13,744 shares of Neurocrine Biosciences worth $1.81M as of Q1 2026.
  • Integrated Wealth Concepts bought 7,085 Neurocrine Biosciences shares in Q1 2026, an estimated $940K.
  • Neurocrine Biosciences made up 0.01% of Integrated Wealth Concepts's portfolio in Q1 2026, its #796 holding.
  • Integrated Wealth Concepts first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 11 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Integrated Wealth Concepts's 13F filing for Q1 2026, filed 15 May 2026.